-- Shanghai Henlius Biotech (HKG:2696) は、中国本土で実施中のHLX319の第1相臨床試験において、最初の被験者への投与を開始した。
この薬剤は、早期乳がん、局所進行乳がん、転移性乳がんの治療を目的としている。
Related Articles
Japan
US 10-Year Treasury Yield Leans Higher at 4.32% Pre-Bell; 2-Year Rate Climbs 1.3 Basis Points to 3.79%
Japan
CGI Launching High-security Sovereign AI Platform in Finland For Enterprise and Public Sector Use
$GIB-A.TO
Research
Mizuho Downgrades Adobe to Neutral From Outperform, Adjusts Price Target to $270 From $315
Adobe (ADBE) has an average rating of overweight and mean price target of $321.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ADBE